Press Releases

ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

ITM Multiplies Production Capacity for its n.c.a. Lutetium-177

ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network

ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022

ITM Acquires a New Platform for the Development of Next-Generation Theranostics

ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board

ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177

ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope

ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress

ITM to Host Scientific Precision Oncology Symposium in Parallel to the ASCO Annual Meeting on Friday, June 03, 2022

ITM kündigt Symposium und Präsenz auf der 60. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig an

ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177

ITM Announces Successful Completion of Patient Recruitment for its Phase III Trial, COMPETE, with Lead Radiotherapeutic ITM-11 (n.c.a. lutetium-177-edotreotide)